Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab

BACKGROUND: In the FIRE-3 trial, overall survival (OS) was significantly longer in patients treated with FOLFIRI plus cetuximab (C-mab) than in those treated with FOLFIRI plus bevacizumab (Bev), but progression-free survival (PFS) was not significantly different. This may be associated with the deep...

Descripción completa

Detalles Bibliográficos
Autores principales: Osumi, Hiroki, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532210/
https://www.ncbi.nlm.nih.gov/pubmed/26273206
http://dx.doi.org/10.2147/OTT.S87101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532210/
https://www.ncbi.nlm.nih.gov/pubmed/26273206
http://dx.doi.org/10.2147/OTT.S87101

Ejemplares similares